Navigation Links
Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Date:10/31/2013

t per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012Revenues:Net revenues

$

1,756,046$

1,789,836$

5,062,791$

5,040,896Other revenues

11,38011,95037,82632,360Total revenues

1,767,4261,801,7865,100,6175,073,256Cost of sales

958,9081,008,6642,856,2252,907,268Gross profit

808,518793,1222,244,3922,165,988Operating expenses:Research and development

113,995108,250351,914283,570Selling, general and administrative

364,868342,2321,031,6241,037,802Litigation settlements, net

(10,161)7,950(1,428)(2,083)Total operating expenses

468,702458,4321,382,1101,319,289Earnings from operations

339,816334,690862,282846,699Interest expense

73,95376,051233,744234,126Other (expense) income, net

(70,597)6,209(74,391)604Earnings before income taxes and noncontrolling interest

195,266264,848554,147613,177Income tax provision

35,84352,762108,564132,449Net earnings

159,423212,086445,583480,728Net earnings attributable to the noncontrolling interest

(515)(829)(2,104)(1,842)Net earnings attributable to Mylan Inc. common shareholders

$

158,908$

211,257$

443,479$

478,886Earnings per common share attributable to Mylan Inc. common shareholders:Basic

$

0.42$

0.52$

1.15$

1.15Diluted

$

0.40$

0.51$

1.13$

1.13Weighted average common shares outstanding:Basic

382,134406,469385,497418,000Diluted

395,548411,562393,872422,775Note
Certain insignificant prior period amounts of other revenue, cost of sales and operating expenses have been reclassified to other (expense) income, net to conform to the presentation for the current period. The reclassifications had no impact on our previously reported net earnings attributable to Mylan Inc.
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
2. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
3. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
6. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
7. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
8. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
9. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
10. Roger Graham Named President of Mylan Specialty
11. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ) ... and long-term growth strategies at a meeting with the ... . President and Chief Executive Officer Mike ... has to bring forward meaningful innovation to transform patient ... shareholder value. "We are focused on ...
(Date:5/1/2015)... May 1, 2015 Cambrex Corporation (NYSE: CBM ... 2015. Highlights , Sales increased ... 27% excluding foreign currency impact, driven by Innovator products and ... $8.4 million in the first quarter of 2014. , ... in the first quarter last year and Adjusted Diluted EPS ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
... magazine has ranked Universal SmartComp #503 overall and #35 ... 5000, an exclusive ranking of the nation,s fastest-growing private ... the most important segment of the economy—America,s independent-minded entrepreneurs. ... and Radio Flyer, maker of the iconic children,s red ...
Cached Medicine Technology:Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3
(Date:5/3/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... She has worked to enhance the well being of the men, ... generalist in a hospital, followed by providing care for families in ... with as an Adult Nurse Practitioner began wondering if I could ... the birth of my own children with my mentor Nurse Midwife, ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... 2015 " Bubbly Walrus ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... game. , The best games to play on smartphones are ... users killing brain cells with a video game that just ...
(Date:5/3/2015)... 2015 “ BolehVPN ” was featured on ... the latest and coolest technology products available to consumers. Scott ... the review and shared with viewers how to protect their ... days is on computers and even more so online. It ... people all over the world. In terms of work, the ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 NuevaCare announced ... at two upcoming area seminars. The first event will ... Annual Regional Stroke Conference to be held at The ... on Wednesday, May 13 during the Dementia Conference to ... , “These seminars offer an excellent opportunity to learn ...
Breaking Medicine News(10 mins):Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... found out that a protein called NMNAT can delay the ... level. The researchers from Baylor College of// Medicine in a ... online today said that NMNAT protects against nerve cell degeneration ... the question if a drug might be developed that could ...
... wines that belong to the vineyards of France and Italy are ... effects of fatty meals on the heart can be offset by ... has shown. Wines from these regions contain high levels of a ... have also proved the heart healthy benefits of a daily glass ...
... Center and colleagues at four other medical centers have ... that may contribute to early atherosclerosis. ,“If we ... life who have a genetic predisposition to develop atherosclerosis, ... and stroke sooner and more aggressively,” said David Herrington, ...
... a new drug that might cease men from ejaculation during ... on is that the contraction of the longitudinal muscle in ... out of the penis. ,This method of contraception ... to which researchers claim have chemicals to block male sperms. ...
... unknown immunodeficiency disease was discovered by scientists about twenty-five ... 'AIDS'. //Ever since, 'Acquired Immune Deficiency Syndrome' or AIDS, ... to the latest figures enabled by the UNAIDS/WHO 2006 ... world are grappling with the disease. ,AIDS ...
... Research, the data from Population Based Cancer Registry, Delhi ... specific// incidence rates of breast cancer below 40 years ... National Cancer Control Programme (NCCP), special emphasis is now ... awareness. Grant-in-aid is provided to Non-Governmental Organisations to create ...
Cached Medicine News:Health News:NMNAT Protein Protects Against Nerve Cell Degeneration 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 3Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 4
... proteins produced with recombinant technology, that have been ... capable of detecting the different types of T.cruzi ... with amino acid sequences repeated in tandem. SAPA ... phase of the infection, it reacts with 93% ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
... defibrillator lead features a patented ... flexibility and maneuverability of a ... physician who prefers a lead ... SPL lead also promotes low ...
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
Medicine Products: